TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7770614

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study: 2186476

Group type: EXPERIMENTAL
Intervention: MaxEPA
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (olive oil)
Number of subjects: 17
Study: 658107

Group type: EXPERIMENTAL
Intervention: bendroflumethiazide (bft) 2.5 mg and KCl 1.5 g daily for 2 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: bendroflumethiazide (bft) 5 mg and KCl 1.5 g daily for 2 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo treatment for 4 weeks
Number of subjects: 8
Study: 30563770

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPI)
Number of subjects: 10942

Group type: COMPARATOR
Intervention: Non-Glycoprotein IIb/IIIa inhibitors (non-GPI)
Number of subjects: 10942
Study: 28482901

Group type: EXPERIMENTAL
Intervention: Daily listening to specially composed songs for 12 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Daily relaxation for 12 weeks
Number of subjects: 111
Study: 25218898

Group type: EXPERIMENTAL
Intervention: Cortisol TRAJ group membership (high vs. low cortisol)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Low cortisol TRAJ group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High cortisol TRAJ group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cumulative inflammatory load score (ILS)
Number of subjects: 91
Study: 23023407

Group type: EXPERIMENTAL
Intervention: 0.1% pranoprofen (PN) eye drops, 4 times daily for 4 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0.1% fluorometholone (FL) eye drops, 4 times daily for 4 weeks
Number of subjects: 75
Study: 21613025

Group type: EXPERIMENTAL
Intervention: Dentin desensitizer and ozone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 19111473

Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg/(m2 12 h), days 1‐14 plus oxaliplatin 130 mg/m2 day 1, every 3 weeks
Number of subjects: 348

Group type: COMPARATOR
Intervention: Weekly infusional 5‐FU 2250 mg/m2 over 48 h plus bimonthly oxaliplatin 85 mg/m2
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Capecitabine plus oxaliplatin
Number of subjects: 348

Group type: COMPARATOR
Intervention: Weekly infusional 5‐FU plus oxaliplatin
Number of subjects: 348
Study: 16710073

Group type: EXPERIMENTAL
Intervention: Low-dose pioglitazone (7.5 mg/day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard-dose pioglitazone (15 mg/day)
Number of subjects: 95
Study: 15080850

Group type: EXPERIMENTAL
Intervention: Lactulose (Duphalac)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Polyethylene glycol-4000 (Forlax)
Number of subjects: 65
Study: 11876663

Group type: EXPERIMENTAL
Intervention: Individual treatment
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Group treatment
Number of subjects: 248

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 248
Study: 9846303

Group type: EXPERIMENTAL
Intervention: Partial left lateralization (20 degrees)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 204
Study: 7866597

Group type: EXPERIMENTAL
Intervention: Low dose acetylsalicylic acid (ASA, aspirin) 75 mg daily
Number of subjects: 19196

Group type: EXPERIMENTAL
Intervention: Calcium antagonist felodipine 5 mg daily
Number of subjects: 19196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19196
Study: 2770103

Group type: EXPERIMENTAL
Intervention: 1% amino acid dialysis solution
Number of subjects: 6
Study: 269880

Group type: EXPERIMENTAL
Intervention: Pluronic F‐127 plus sodium citrate gel
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Pluronic F‐127 gel
Number of subjects: 176

Group type: COMPARATOR
Intervention: Strontium chloride dentifrice
Number of subjects: 176

Group type: COMPARATOR
Intervention: 0.4% stannous fluoride gel
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 176
Study: 27820659

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA)
Number of subjects: 15187

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) alone
Number of subjects: 15187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15187
Study: 26028283

Group type: EXPERIMENTAL
Intervention: Fasting/exercise/saline infusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fasting/rest/saline (control)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fasting/rest/iv glucose infusions
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fasting/rest/saline
Number of subjects: 23
Study: 24015701

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Maltodextrin placebo control
Number of subjects: 10
Study: 21991787

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS) for 72 hours
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 80
Study: 19156856

Group type: EXPERIMENTAL
Intervention: Participation in the ETS reduction trial
Number of subjects: 153

Group type: COMPARATOR
Intervention: Non-participation in the ETS reduction trial
Number of subjects: 153

Group type: COMPARATOR
Intervention: Primary caregiver being a smoker
Number of subjects: 153

Group type: COMPARATOR
Intervention: Primary caregiver being female
Number of subjects: 153

Group type: COMPARATOR
Intervention: CNS tumor diagnosis
Number of subjects: 153

Group type: COMPARATOR
Intervention: No history of chemotherapy
Number of subjects: 153

Group type: COMPARATOR
Intervention: History of surgery prior to study recruitment
Number of subjects: 153

Group type: COMPARATOR
Intervention: Future radiation therapy planned post study recruitment
Number of subjects: 153
Study: 16708043

Group type: EXPERIMENTAL
Intervention: Client Adherence Profiling and Intervention Tailoring (CAP-IT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 240
Study: 15119910

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT), administered 3 times weekly
Number of subjects: 253
Study: 11157412

Group type: EXPERIMENTAL
Intervention: Irregular menstrual cycles
Number of subjects: 33434

Group type: EXPERIMENTAL
Intervention: Irregular menstrual bleeding duration
Number of subjects: 33434

Group type: EXPERIMENTAL
Intervention: Both irregular menstrual cycles and irregular menstrual bleeding
Number of subjects: 33434

Group type: COMPARATOR
Intervention: One menstrual disturbance
Number of subjects: 33434
Study: 9022435

Group type: EXPERIMENTAL
Intervention: Care provided by practice doctors
Number of subjects: 2152

Group type: COMPARATOR
Intervention: Care provided by deputising doctors
Number of subjects: 2152
Study: 30646153

Group type: EXPERIMENTAL
Intervention: PET-CT plus CT of the abdomen and pelvis
Number of subjects: 171

Group type: COMPARATOR
Intervention: CT of the abdomen and pelvis
Number of subjects: 171
Study: 27302143

Group type: EXPERIMENTAL
Intervention: Mometasone furoate plus sodium hyaluronate (9 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mometasone furoate plus saline solution
Number of subjects: 80
Study: 25609319

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (CHO)
Number of subjects: 120
Study: 23560256

Group type: EXPERIMENTAL
Intervention: RelyX Unicem with polyacrylic acid pretreatment (RLXU-P)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Maxcem Elite with polyacrylic acid pretreatment (MCE-P)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RLXU)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Maxcem Elite (MCE)
Number of subjects: 56

Group type: COMPARATOR
Intervention: RelyX ARC (ARC)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: SeT (ST)
Number of subjects: 56
Study: 19036898

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: NOS inhibition (10 mM N(G)-nitro-l-arginine methyl ester)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 14
Study: 17382603

Group type: EXPERIMENTAL
Intervention: Rifaximin 200 mg 3 times daily for 3 days
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Rifaximin-loperamide combination therapy
Number of subjects: 310

Group type: COMPARATOR
Intervention: Loperamide (4 mg initially followed by 2 mg after each unformed stool)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Rifaximin
Number of subjects: 310

Group type: COMPARATOR
Intervention: Loperamide alone
Number of subjects: 310
Study: 14711550

Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (50 microg/d of E(2) and 140-170 microg/d of norethisterone acetate; n = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral hormone therapy (2 mg of E(2) and 1 mg of norethisterone acetate; n = 12)
Number of subjects: 24
Study: 11290880

Group type: EXPERIMENTAL
Intervention: Donepezil (DPZ) 5-10 mg/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rivastigmine (Riv) 1.5 to 12 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin E 2,000 IU/d
Number of subjects: 60
Study: 9868823

Group type: EXPERIMENTAL
Intervention: Education in psychiatric nursing
Number of subjects: 0
Study: 8049645

Group type: EXPERIMENTAL
Intervention: Cytotoxic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibacterial prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New growth factors
Number of subjects: 0
Study: 2465391

Group type: COMPARATOR
Intervention: PVP16B (cisplatin plus etoposide plus bleomycin) administered in three courses over 9 weeks
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: PVP16B (cisplatin plus etoposide plus bleomycin) administered in four courses over 12 weeks
Number of subjects: 184
Study: 958261

Group type: EXPERIMENTAL
Intervention: Chlorambucil plus prednisone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 21
Study: 30880470

Group type: EXPERIMENTAL
Intervention: Local-only anesthesia
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sedation
Number of subjects: 31
Study: 31218480

Group type: EXPERIMENTAL
Intervention: Training initiative in person-centered care planning
Number of subjects: 7
Study: 28709155

Group type: EXPERIMENTAL
Intervention: Electrocardiographic chest strap monitor (Polar H7)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Apple Watch
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TomTom Spark
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Garmin Forerunner 235
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Scosche Rhythm+
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fitbit Blaze
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bicycling exercise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Elliptical trainer without arm levers
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Elliptical trainer with arm levers
Number of subjects: 50
Study: 26052831

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (optimal facilitation)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Dissonance-based intervention
Number of subjects: 347

Group type: COMPARATOR
Intervention: Classes as usual control
Number of subjects: 347
Study: 23534025

Group type: EXPERIMENTAL
Intervention: Indirect resin composite veneers (Estenia)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ceramic laminate veneers (IPS Empress Esthetic)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Resin composite laminate veneers
Number of subjects: 10
Study: 21639941

Group type: EXPERIMENTAL
Intervention: Acupuncture (AC)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 102
Study: 19502254

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study: 16857301

Group type: EXPERIMENTAL
Intervention: Integrative learning approach
Number of subjects: 97

Group type: COMPARATOR
Intervention: Low levels of computer anxiety
Number of subjects: 97
Study: 15554757

Group type: EXPERIMENTAL
Intervention: Topiramate (titrated from 25 mg/day to a maximum of 600 mg/day)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Topiramate (during controlled and open-label studies)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Topiramate (only during the open-label trial)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Topiramate (not specified dosage)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 11470302

Group type: EXPERIMENTAL
Intervention: Stretching the ankle to a fixed dorsiflexion angle for 20 min followed by a 2 min release (subjects either relaxed or performed isometric contractions)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Stretching the ankle for 20 min, then releasing between 0 and 20 min, then stretching again (24 subjects)
Number of subjects: 8
Study: 9778280

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 2 mg twice daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 7523607

Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM (n = 8)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ProMACE-MOPP (n = 9)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ProMACE/MOPP flexitherapy (n = 8)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ProMACE-MOPP and ProMACE/MOPP flexitherapy combined
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Localized disease treatment (MOPP plus radiation)
Number of subjects: 33
Study: 3220232

Group type: EXPERIMENTAL
Intervention: Acetorphan (2.5 mg/kg intravenously at a constant rate in 20 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30548111

Group type: EXPERIMENTAL
Intervention: Activity-oriented therapy (cooking)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Paper-based activities
Number of subjects: 7
Study: 29706047

Group type: EXPERIMENTAL
Intervention: Qilin Pills (6 g tid for 12 weeks)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Wuziyanzong Pills (6 g bid for 12 weeks)
Number of subjects: 216
Study: 26714371

Group type: EXPERIMENTAL
Intervention: Water exercise
Number of subjects: 88

Group type: COMPARATOR
Intervention: Land exercise
Number of subjects: 88
Study: 23400750

Group type: EXPERIMENTAL
Intervention: Intravaginal taggant (2‐butyl acetate, 2‐pentyl acetate, isopropyl butyrate, or 2‐pentyl butyrate; 30 mg) in hydroxyethylcellulose or tenofovir placebo gel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dermal administration of the same formulations
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravaginal taggant
Number of subjects: 12
Study: 20512389

Group type: EXPERIMENTAL
Intervention: Test tablets containing bovine lactoferrin and lactoperoxidase
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 15
Study: 19250310

Group type: EXPERIMENTAL
Intervention: 20 U of BoNT‐A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 U of BoNT‐A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both doses of BoNT‐A (20 U and 30 U)
Number of subjects: 0
Study: 17295590

Group type: EXPERIMENTAL
Intervention: diazepam 0.1 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 14965847

Group type: EXPERIMENTAL
Intervention: Optimal maternal and paternal bonding profiles (high care/low overprotection)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Maternal care
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Paternal overprotection
Number of subjects: 246
Study: 11221825

Group type: EXPERIMENTAL
Intervention: Homozygous APC variant genotype
Number of subjects: 3580

Group type: EXPERIMENTAL
Intervention: Homozygous APC variant genotype diagnosed after age 65
Number of subjects: 3580

Group type: EXPERIMENTAL
Intervention: Homozygous APC variant genotype with low-fat diet
Number of subjects: 3580

Group type: COMPARATOR
Intervention: Control group (homozygote wild type)
Number of subjects: 3580
Study: 9621667

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg.kg‐1) with lidocaine (group ML)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg.kg‐1) (group L)
Number of subjects: 27
Study: 7921861

Group type: EXPERIMENTAL
Intervention: 1.25 micrograms of intrathecal fentanyl
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 79
Study: 3052813

Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30792007

Group type: EXPERIMENTAL
Intervention: BUP‐XR 300 mg/300 mg
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: BUP‐XR 300 mg/100 mg
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study: 30107404

Group type: EXPERIMENTAL
Intervention: Fronto-temporal transcranial direct current stimulation (tDCS) with 2-mA, twice-daily sessions for 5 consecutive days.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 60
Study: 26735919

Group type: EXPERIMENTAL
Intervention: 2-hour reduction in daily sitting
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: accumulating 30 additional brief sit‐to‐stand transitions per day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study: 24473220

Group type: EXPERIMENTAL
Intervention: Private rehabilitation
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Public rehabilitation
Number of subjects: 4000
Study: 22551119

Group type: EXPERIMENTAL
Intervention: Daily intake of 150 ml tomato juice (15 mg lycopene) for 5 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no tomato juice intake during wash-out period)
Number of subjects: 15
Study: 20705564

Group type: EXPERIMENTAL
Intervention: Docetaxel plus Bevacizumab
Number of subjects: 76
Study: 17641547

Group type: EXPERIMENTAL
Intervention: r19‐kD protein
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: skin prick tests
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: r19‐kD protein sIgE ELISAs
Number of subjects: 37

Group type: COMPARATOR
Intervention: BW sIgE coated allergen particle test
Number of subjects: 37
Study: 15761090

Group type: EXPERIMENTAL
Intervention: Temperature at 39 degrees C (T2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Temperature at 45 degrees C (T3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Temperature at 33 degrees C (T1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Temperature increase from T1 to T3
Number of subjects: 12
Study: 12410473

Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil (A-P)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 10465129

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g three times daily
Number of subjects: 148

Group type: COMPARATOR
Intervention: Cefepime 2 g twice daily
Number of subjects: 148
Study: 8591679

Group type: EXPERIMENTAL
Intervention: Individualized developmentally oriented care plans
Number of subjects: 40
Study: 1693738

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Metoprolol (added after 8 weeks for uncontrolled patients)
Number of subjects: 45
Study: 157076

Group type: EXPERIMENTAL
Intervention: Metronidazole (200 mg or 400 mg three times daily for 10 days)
Number of subjects: 75
Study: 30975539

Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation intervention (behavioral support and pharmacological aids)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Usual care (access to local smoking cessation services)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation intervention
Number of subjects: 526
Study: 28493502

Group type: EXPERIMENTAL
Intervention: fasiglifam 50 mg
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: fasiglifam 25 mg
Number of subjects: 421

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 421
Study: 26051566

Group type: EXPERIMENTAL
Intervention: Topical application of 100% lavender essential oil
Number of subjects: 34

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (with water)
Number of subjects: 34
Study: 23343319

Group type: EXPERIMENTAL
Intervention: School nurse-delivered counseling intervention utilizing cognitive-behavioral techniques
Number of subjects: 84

Group type: COMPARATOR
Intervention: Nurse contact with provision of information
Number of subjects: 84
Study: 21366756

Group type: EXPERIMENTAL
Intervention: Family home visiting services for mothers with ID
Number of subjects: 68

Group type: COMPARATOR
Intervention: Family home visiting services for mothers without ID
Number of subjects: 68
Study: 18824040

Group type: EXPERIMENTAL
Intervention: Cortisol (30 mg oral dose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 17911367

Group type: EXPERIMENTAL
Intervention: Integrated model of care (all MH/SA services provided at primary care clinics)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Enhanced referral model of care (all MH/SA services provided at specialized MH clinics)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Integrated model of care
Number of subjects: 183

Group type: COMPARATOR
Intervention: Enhanced referral model of care
Number of subjects: 183
Study: 15538933

Group type: EXPERIMENTAL
Intervention: GHRH antagonist (N‐Ac‐Tyr(1), D‐Arg(2)) GHRH‐29 (NH(2))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study: 11288008

Group type: EXPERIMENTAL
Intervention: Acute arthroscopic repair (28 patients; 22 with transglenoid suture, 6 with bone anchor suture fixation)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nonoperative treatment (18 patients)
Number of subjects: 46
Study: 9040547

Group type: EXPERIMENTAL
Intervention: 30 mg of zinc per day for the first 3 days of TPN
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0 mg of zinc per day for the first 3 days of TPN
Number of subjects: 44